down arrow

Bio-Rad Laboratories, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0905722072
USD
320.06
-0.28 (-0.09%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

312.58320.42

52 Week

211.43373.69
Valuation
Technical
Day's Volume

CASH

26.11 k

Shareholding (Mar 2025)

FII

21.66%

Held by 282 FIIs

DII

27.4%

Held by 55 DIIs

Promoter

1.01%

How big is Bio-Rad Laboratories, Inc.?

22-Jun-2025

As of Jun 18, Bio-Rad Laboratories, Inc. has a market capitalization of $6.34 billion, with net sales of $2.54 billion and a net profit of -$2.16 billion over the latest four quarters.

Market Cap: As of Jun 18, Bio-Rad Laboratories, Inc. has a market capitalization of 6,337.14 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Bio-Rad Laboratories, Inc. reported net sales of 2,541.11 million and a net profit of -2,164.12 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 6,569.30 million and total assets of 9,364.10 million.

Read More

What does Bio-Rad Laboratories, Inc. do?

22-Jun-2025

Bio-Rad Laboratories, Inc. manufactures products for life science research, healthcare, and analytical chemistry, with a market cap of approximately $6.34 billion. As of March 2025, it reported net sales of $585 million and a net profit of $64 million.

Overview: <BR>Bio-Rad Laboratories, Inc. manufactures and supplies products and systems for life science research, healthcare, and analytical chemistry, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 585 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 64 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 6,337.14 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 5.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.06 <BR>Return on Equity: 17.30% <BR>Price to Book: 0.95<BR><BR>Contact Details: <BR>Address: 1000 ALFRED NOBEL DR, HERCULES CA: 94547-1811 <BR>Tel: 1 510 7247000 <BR>Website: http://www.bio-rad.com/

Read More

Who are in the management team of Bio-Rad Laboratories, Inc.?

22-Jun-2025

As of March 2022, the management team of Bio-Rad Laboratories, Inc. includes Norman Schwartz (Chairman, President, CEO), Gregory Hinckley (Lead Independent Director), Alice Schwartz, Jeffrey Edwards, Melinda Litherland, and Arnold Pinkston (all Independent Directors).

As of March 2022, the management team of Bio-Rad Laboratories, Inc. includes the following individuals:<BR><BR>- Mr. Norman Schwartz: Chairman of the Board, President, Chief Executive Officer<BR>- Mr. Gregory Hinckley: Lead Independent Director<BR>- Mrs. Alice Schwartz: Director<BR>- Mr. Jeffrey Edwards: Independent Director<BR>- Ms. Melinda Litherland: Independent Director<BR>- Mr. Arnold Pinkston: Independent Director

Read More

Is Bio-Rad Laboratories, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Bio-Rad Laboratories, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -12.79% compared to the benchmark's 12.22%.

As of 25 August 2025, the technical trend for Bio-Rad Laboratories, Inc. has changed from sideways to mildly bearish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum in the short term. However, the daily moving averages are mildly bearish, and the Bollinger Bands show a bearish signal on the monthly timeframe. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish across both timeframes. Overall, the indicators suggest a mildly bearish stance.<BR><BR>In terms of performance, Bio-Rad has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.79% compared to the S&P 500's 12.22%, and a one-year return of -15.85% versus 17.14% for the benchmark.

Read More

Is Bio-Rad Laboratories, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Bio-Rad Laboratories, Inc. is considered fairly valued with a P/E ratio of 5 and a significant discount compared to peers, but its stock has underperformed the S&P 500 with a year-to-date return of -5.63% and a five-year return of -44.30%.

As of 17 October 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 5, a Price to Book Value of 0.91, and an EV to EBITDA of 10.62. In comparison to peers, Hologic, Inc. has a P/E ratio of 21.83, while QIAGEN NV stands at 24.20, suggesting that Bio-Rad is trading at a significant discount relative to these competitors.<BR><BR>Despite the recent fair valuation, Bio-Rad's stock performance has lagged behind the S&P 500, with a year-to-date return of -5.63% compared to the index's 13.30%. Over the past five years, the company's return has been -44.30%, while the S&P 500 has gained 91.29%. This underperformance reinforces the notion that Bio-Rad is fairly valued, as it struggles to keep pace with broader market trends.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of 2.18% over the last 5 years

 
2

The company has declared negative results in Mar'2025 after 3 consecutive positive quarters

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7,937 Million (Small Cap)

stock-summary
P/E

5.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

6.87%

stock-summary
Price to Book

1.11

Revenue and Profits:
Net Sales:
652 Million
(Quarterly Results - Jun 2025)
Net Profit:
318 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.58%
0%
10.58%
6 Months
44.14%
0%
44.14%
1 Year
-5.43%
0%
-5.43%
2 Years
3.6%
0%
3.6%
3 Years
-23.62%
0%
-23.62%
4 Years
-56.83%
0%
-56.83%
5 Years
-42.79%
0%
-42.79%

Bio-Rad Laboratories, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Bio-Rad Laboratories Adjusts Valuation Amidst Financial Performance Challenges and Market Reassessment

Bio-Rad Laboratories Adjusts Valuation Amidst Financial Performance Challenges and Market Reassessment

Bio-Rad Laboratories, Inc. has experienced a change in its valuation grade, now categorized as fair. This adjustment is based on a reassessment of financial metrics, including a P/E ratio of 16.20 and a price-to-book value of 0.91, alongside challenges in sales growth and recent profit declines.

Read More

Is Bio-Rad Laboratories, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 5, a Price to Book Value of 0.91, and an EV to EBITDA of 10.62. In comparison to peers, Hologic, Inc. has a P/E ratio of 21.83, while QIAGEN NV stands at 24.20, suggesting that Bio-Rad is trading at a significant discount relative to these competitors. Despite the recent fair valuation, Bio-Rad's stock performance has lagged behind the S&P 500, with a year-to-date return of -5.63% compared to the index's 13.30%. Over the past five years, the company's return has been -44.30%, while the S&P 500 has gained 91.29%. This underperformance reinforces the notion that Bio-Rad is fairly valued, as it struggles to keep pace with broader market trends....

Read More
Bio-Rad Laboratories Experiences Valuation Adjustment Amid Competitive Market Landscape

Bio-Rad Laboratories Experiences Valuation Adjustment Amid Competitive Market Landscape

Bio-Rad Laboratories, Inc. has recently adjusted its valuation, reporting a P/E ratio of 5 and a low PEG ratio of 0.07. Its performance indicators reveal a year-to-date return of -5.63%, contrasting with the S&P 500's gain, underscoring the challenges in a competitive Pharmaceuticals & Biotechnology sector.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.18%
EBIT Growth (5y)
2.95%
EBIT to Interest (avg)
30.77
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
0.29
Tax Ratio
21.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
4.97%
ROE (avg)
11.09%
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
0.91
EV to EBIT
16.72
EV to EBITDA
10.62
EV to Capital Employed
0.90
EV to Sales
2.21
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
5.38%
ROE (Latest)
17.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 112 Schemes (49.9%)

Foreign Institutions

Held by 282 Foreign Institutions (21.66%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 11.31% vs -12.30% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 396.56% vs 108.94% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "651.60",
          "val2": "585.40",
          "chgp": "11.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "130.10",
          "val2": "105.10",
          "chgp": "23.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "12.60",
          "val2": "12.00",
          "chgp": "5.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "332.00",
          "val2": "-1.40",
          "chgp": "23,814.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "317.80",
          "val2": "64.00",
          "chgp": "396.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "122.00%",
          "val2": "97.20%",
          "chgp": "2.48%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -3.92% vs -4.67% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -189.38% vs 82.43% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,566.50",
          "val2": "2,671.30",
          "chgp": "-3.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "503.80",
          "val2": "576.20",
          "chgp": "-12.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "48.90",
          "val2": "49.40",
          "chgp": "-1.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2,698.80",
          "val2": "-1,295.80",
          "chgp": "-108.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,844.20",
          "val2": "-637.30",
          "chgp": "-189.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "121.20%",
          "val2": "143.70%",
          "chgp": "-2.25%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
651.60
585.40
11.31%
Operating Profit (PBDIT) excl Other Income
130.10
105.10
23.79%
Interest
12.60
12.00
5.00%
Exceptional Items
332.00
-1.40
23,814.29%
Consolidate Net Profit
317.80
64.00
396.56%
Operating Profit Margin (Excl OI)
122.00%
97.20%
2.48%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 11.31% vs -12.30% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 396.56% vs 108.94% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,566.50
2,671.30
-3.92%
Operating Profit (PBDIT) excl Other Income
503.80
576.20
-12.57%
Interest
48.90
49.40
-1.01%
Exceptional Items
-2,698.80
-1,295.80
-108.27%
Consolidate Net Profit
-1,844.20
-637.30
-189.38%
Operating Profit Margin (Excl OI)
121.20%
143.70%
-2.25%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -3.92% vs -4.67% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -189.38% vs 82.43% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Bio-Rad Laboratories, Inc. stock-summary
stock-summary
Bio-Rad Laboratories, Inc.
Pharmaceuticals & Biotechnology
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.
Company Coordinates stock-summary
Company Details
1000 ALFRED NOBEL DR , HERCULES CA : 94547-1811
stock-summary
Tel: 1 510 7247000
stock-summary
http://www.bio-rad.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."